FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Described is a method of increasing polynucleotide expression of pyrroline-5-carboxylate reductase 1 (PYCR1) in a patient's cells or tissues in vivo or in vitro, involving: bringing said cells or tissues into contact with an oligonucleotide, in particular with oligonucleotide of small interfering RNA (siRNA), varying in length from 20 to 30 nucleotides, which is specifically hybridised with and is aimed at portion of natural antisense PYCR1. Disclosed is a synthetic oligonucleotide comprising 20–30 nucleotides in length, containing optional modifications, wherein said modifications are selected from at least one modified sugar fragment; at least one modified internucleotide linkage; at least one modified nucleotide; and combinations thereof; wherein said oligonucleotide is specific for and specifically hybridised with natural antisense polynucleotide PYCR1 and increases expression of polynucleotide PYCR1, having a sequence of SEQ ID NO: 1, in mammal cells or tissues in vivo or in vitro, wherein said natural antisense polynucleotide is selected from SEQ ID NO: 2.
EFFECT: invention also discloses a method of preventing or treating a disease associated with at least one polynucleotide PYCR1 and/or, at least one product coded by said polynucleotide, involving administering a therapeutically effective dose of at least one of said oligonucleotide and a composition containing said oligonucleotide.
26 cl, 1 dwg, 1 tbl, 2 ex
